Molex, parent company of Phillips Medisize, has announced that it has signed an agreement to purchase Vectura Group Limited, a leader in inhalation drug device design and formulation.
A peer reviewed study published in Frontiers in Neuroscience has shown that Ellorarxine, a novel drug compound developed by biotech spinout Nevrargenics, has shown a robust neuroprotective effect in cultured cells and reaches its target in animals.
DevCo Partners Ltd has announced a capital raise resulting in 616 MEUR of total commitments for its long-term single asset investment vehicle for Medix Biochemica.
Bayer is taking a step in the emerging healthy-ageing space by offering consumers new tools to help them support their healthy-ageing journey with its new Age Factor ecosystem.
Renato Rjavec, ArisGlobal, discusses how generative AI (GenAI) technology is transforming everyday regulatory and safety processes, thanks to its ability to summarise key insights and findings from across huge, diverse bodies of content and data.
MSD and Curon have announced that they have entered into a definitive agreement under which MSD has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.
Alcura, a provider of specialised clinical trial services and a part of Cencora, has been granted a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) by the Spanish Agency of Medicines and Medical Devices.
Packaging is a critical component of pharmaceuticals, protecting the integrity, safety, and efficacy of essential treatments throughout the supply chain and providing tools for product traceability. James Bury, director technology, Tjoapack explains.
